Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead's Bictegravir Demonstrates Broad Non-Inferiority, But Will That Suffice?

Executive Summary

Having lost market share in recent years to HIV regimens containing ViiV's Tivicay, will a showing of non-inferiority across four head-to-head Phase III studies give bictegravir the market edge Gilead seeks?

You may also be interested in...



Gilead's Strong HIV Quarter Plus Bictegravir May Portend Sector Dominance

Sales of Gilead's TAF-based regimens for HIV continue to grow and should be augmented by elvitegravir successor bictegravir. The company's future growth is unclear, however, without M&A.

Keeping Track: HIV Filings Include Novel Agent From Gilead, Viiv's Two-Drug Maintenance Regimen

The latest HIV drug development news and highlights from our FDA Performance Tracker.

ViiV/Janssen Forge Two-Drug Future For HIV With SWORD Filings

The battle of the HIV giants ViiV Healthcare and Gilead Sciences continues with the first filing for a two-drug regimen for use against HIV infection in the US and EU.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC098825

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel